DE60331941D1 - Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert - Google Patents

Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert

Info

Publication number
DE60331941D1
DE60331941D1 DE60331941T DE60331941T DE60331941D1 DE 60331941 D1 DE60331941 D1 DE 60331941D1 DE 60331941 T DE60331941 T DE 60331941T DE 60331941 T DE60331941 T DE 60331941T DE 60331941 D1 DE60331941 D1 DE 60331941D1
Authority
DE
Germany
Prior art keywords
disease
fibrostenosis
crohn
fibrostenosing
nod2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331941T
Other languages
German (de)
English (en)
Inventor
Maria T Abreu
Kent D Taylor
Jerome I Rotter
Huiying Yang
Kazuhito Sugimura
Stephan R Targan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of DE60331941D1 publication Critical patent/DE60331941D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60331941T 2002-08-30 2003-07-30 Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert Expired - Lifetime DE60331941D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40739102P 2002-08-30 2002-08-30
US10/356,736 US20040053263A1 (en) 2002-08-30 2003-01-30 Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
PCT/US2003/023926 WO2004020968A2 (en) 2002-08-30 2003-07-30 Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease

Publications (1)

Publication Number Publication Date
DE60331941D1 true DE60331941D1 (de) 2010-05-12

Family

ID=31981139

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331941T Expired - Lifetime DE60331941D1 (de) 2002-08-30 2003-07-30 Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert

Country Status (7)

Country Link
US (2) US20040053263A1 (https=)
EP (1) EP1556405B1 (https=)
JP (2) JP4606877B2 (https=)
AT (1) ATE462710T1 (https=)
AU (1) AU2003263834A1 (https=)
DE (1) DE60331941D1 (https=)
WO (1) WO2004020968A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828132B2 (en) * 2001-03-01 2004-12-07 Ultra Biotech Limited Biological fertilizer compositions comprising garbage
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7592150B2 (en) * 2003-12-03 2009-09-22 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
EP1692519B1 (en) * 2003-12-03 2010-06-02 Glycominds Ltd. Method for diagnosing diseases based on levels of anti-glycan antibodies
US20060205022A1 (en) * 2003-12-03 2006-09-14 Nir Dotan Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease
DE112005001317A5 (de) * 2004-03-27 2007-05-24 Klein, Hanns-Georg, Dr. Polymorphismen im NOD2/Card15 Gen
US20080260753A1 (en) * 2004-04-09 2008-10-23 The Regents Of The University Of California Mouse Models of Crohn's Disease and a Method to Develop Specific Therapeutics
US10544459B2 (en) * 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
US20100021455A1 (en) * 2004-12-08 2010-01-28 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
WO2010048415A1 (en) * 2008-10-22 2010-04-29 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
CA2658563A1 (en) * 2006-07-26 2008-01-31 Genizon Biosciences Inc. Crohn disease susceptibility gene
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
JP2010522537A (ja) * 2006-11-30 2010-07-08 ナビジェニクス インコーポレイティド 遺伝子分析系および方法
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2009069007A2 (en) * 2007-11-30 2009-06-04 Glycominds, Ltd. Composition and method for prediction of complicated disease course and surgeries in crohn's disease
WO2009143278A2 (en) * 2008-05-20 2009-11-26 Cedars-Sinai Medical Center Methods of diagnosing and characterizing cannabinoid signaling in crohn's disease
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
CA2758531C (en) 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
WO2011088306A1 (en) * 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose crohn's disease
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
CA2830362A1 (en) * 2011-03-25 2012-10-04 Dermot P. Mcgovern Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
SG11201401536QA (en) 2011-10-21 2014-05-29 Nestec Sa Methods for improving inflammatory bowel disease diagnosis
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
KR20260048600A (ko) 2015-03-27 2026-04-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 t 세포 및 이의 제조 및 사용 방법
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
US11913015B2 (en) 2017-04-17 2024-02-27 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
CA3124970A1 (en) * 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
WO2021097131A1 (en) * 2019-11-12 2021-05-20 Orchard Therapeutics (Europe) Limited Compositions and methods for treating or preventing crohn's disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157053B2 (ja) * 1992-09-16 2001-04-16 ティーディーケイ株式会社 Ｄｎａ作用物質の結合様式特定方法
US5830675A (en) * 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
EP0615129B1 (en) * 1993-03-10 2000-05-31 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6074835A (en) * 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
WO1997038642A1 (en) * 1996-04-12 1997-10-23 Cedars-Sinai Medical Center Methods of determining the risk of pouchitis development
US5916748A (en) * 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
JP2001269196A (ja) * 2000-03-24 2001-10-02 Hamamatsu Photonics Kk 被検体核酸の定量方法、および被検体核酸の分子数の計数方法
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

Also Published As

Publication number Publication date
US20040053263A1 (en) 2004-03-18
EP1556405A2 (en) 2005-07-27
JP2006500016A (ja) 2006-01-05
WO2004020968A2 (en) 2004-03-11
US7790370B2 (en) 2010-09-07
AU2003263834A8 (en) 2004-03-19
EP1556405A4 (en) 2007-01-10
JP2011015686A (ja) 2011-01-27
WO2004020968A3 (en) 2004-08-26
ATE462710T1 (de) 2010-04-15
US20070072180A1 (en) 2007-03-29
EP1556405B1 (en) 2010-03-31
AU2003263834A1 (en) 2004-03-19
JP4606877B2 (ja) 2011-01-05

Similar Documents

Publication Publication Date Title
DE60331941D1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
Striegel-Moore et al. Etiology of eating disorders in women
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
Stifano et al. Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis
CA2282746A1 (en) Prediction of coronary artery disease
ATE438407T1 (de) Diagnose, vorbeugung und behandlung von ulcerativer colitis und deren subtypen unter verwendung mikrobieller uc panca antigene
WO2003089897A3 (en) Diagnosis and treatment of vascular disease
EP1718334A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF PREECLAMPSY OR ECLAMPSY
IL171020A (en) Methods for diagnosing or predicting susceptibility to types of crohn's disease
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
DE69231595D1 (de) Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom
Gehrman et al. Twin‐based heritability of actimetry traits
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
Lynch et al. Performance measures in Friedreich ataxia: potential utility as clinical outcome tools
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
WO2001020533A3 (en) Creation of a database of biochemical data and methods of use
Ambrose et al. Gait and cognition in older adults: Insights from the Bronx and Kerala
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
AU4753900A (en) Methods of diagnosing or treating alzheimer's disease
Hurko et al. Neurology and the skin
RU2003107336A (ru) Способ диагностики клинических типов школьной дезадаптации, установления особенностей возрастной динамики и прогноза дезадаптационных состояний детей с легкой умственной отсталостью
WO2003100090A3 (en) Protein c polymorphisms
WO2002053018A3 (en) Method of detecting polymorphisms associated with breast carcinoma in mhc genes
WO2003007801A3 (en) Diagnosis and treatment of vascular disease
ATE441859T1 (de) Verfahren zur diagnose der immunität wiederkehrenden spontanen schwangerschaftsabbruchs sowie verfahren zur behandlung und überwachung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition